Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01481194 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma(ACVDL) | completed | Phase 2 | 35 | Vejle HospitalOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01790737 | First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02(FMG-MM02) | completed | Phase 2 | 80 | Kuopio University HospitalOTHER | 1 | Mar 1, 2019 |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT02275403 | Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma(ACUFOCIN) | completed | Phase 2 | 120 | The Christie NHS Foundation TrustOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT02566265 | Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients(SHIVERING 2) | completed | Phase 2 | 122 | Yale UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01349569 | Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission | completed | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT01698801 | A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 26 | CelgeneINDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01039025 | TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01782963 | Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)(RVD Lite) | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT03000452 | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(FUSION-MM-005) | completed | Phase 2 | 18 | CelgeneINDUSTRY | 6 | Oct 16, 2018 | clinicaltrials |
| NCT02669615 | Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation | completed | Phase 2 | 24 | Medical College of WisconsinOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00001873 | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | completed | Phase 2 | 102 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01706666 | Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01794039 | Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01852799 | A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00064337 | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | completed | Phase 2 | 104 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT02206503 | Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) | completed | Phase 2 | 13 | Fondazione EMN Italy OnlusOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02331368 | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | completed | Phase 2 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01526694 | Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | completed | Phase 2 | 30 | Azienda Ospedaliera di BolzanoOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01985126 | An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD | completed | Phase 2 | 124 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT01478048 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 185 | Bristol-Myers SquibbINDUSTRY | 5 | May 21, 2018 | clinicaltrials |
| NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | completed | Phase 2 | 36 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | Phase 2 | 101 | AmgenINDUSTRY | 2 | May 14, 2018 | clinicaltrials |
| NCT00574288 | Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | completed | Phase 2 | 104 | Janssen Research & Development, LLCINDUSTRY | 4 | Apr 27, 2018 | clinicaltrials |
| NCT01651039 | Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | completed | Phase 2 | 32 | Ajai ChariOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02791373 | Vinorelbine and Gemcitabine in Myeloma(ViGeM) | completed | Phase 2 | 136 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | completed | Phase 1 / Phase 2 | 177 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 65 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01547806 | Collection of Transplant Stem Cells for Plasma Cell Myeloma | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | Phase 1 / Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00287872 | Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00375791 | Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | completed | Phase 2 | 67 | AEterna ZentarisINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00401011 | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 84 | AEterna ZentarisINDUSTRY | 0 | Feb 23, 2018 | clinicaltrials |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | completed | Phase 2 | 13 | Incyte CorporationINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01270932 | Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT00461045 | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | CelgeneINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT00349778 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | completed | Phase 2 | 102 | Stanford UniversityOTHER | 1 | Dec 12, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 1, 2019source: clinicaltrials